Skip to main content

CORT Corcept Therapeutics Incorporated

Healthcare

81.12 Close 10/30
Since 2024-12-02 +37.0%
Open
85.00
High
85.31
Low
80.28
Prev close
85.95
Volume
1.4M
Amplitude
5.85%
P/E
193.1
P/B
12.4
Revenue YoY (TTM)
+16.0%
52W 28.66 126.38

Is Corcept Therapeutics Incorporated a buy? Fundamentals and valuation first

As of 2026-10-30

Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but TTM P/E is Expensive.
TTM P/E 193.14 96th percentile Expensive
Price / book 12.42 94th percentile Expensive
Free-cash-flow yield (%) 1.22 52th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral FCF margin, TTM is Good, but Operating margin, TTM is Average.
ROE, TTM (%) 7.73 59th percentile Good
Operating margin, TTM (%) 0.77 38th percentile Average
FCF margin, TTM (%) 12.87 66th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Revenue growth, TTM YoY is Good, but Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 16.02 70th percentile Good
Diluted EPS growth, TTM YoY (%) -62.83 31th percentile Average
Momentum Neutral 240-day return is Good, but 60-day return is Average.
60-day return (%) -24.85 22th percentile Average
240-day return (%) 7.39 60th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 92,478,292 86th percentile Top
60-day annualized volatility (%) 56.74 61th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Corcept Therapeutics Incorporated (CORT) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Corcept Therapeutics Incorporated to every stock like it

AI finds several complementary traits of Corcept Therapeutics Incorporated across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (CORT) peers and tracking

Watchlist

This page refreshes daily after the close. Add Corcept Therapeutics Incorporated to your watchlist to track signal changes on your next visit.

Corcept Therapeutics Incorporated (CORT) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 92.7%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
24 historical occurrences (since 2016-07-06)

Average forward return after Top-quintile 6-month momentum

20-day: Win 50%, Sample 24, Median -0.21%, Excess -1.38%, Beat mkt rate 41.7%

60-day: Win 50%, Sample 24, Median +3.87%, Excess +4.11%, Beat mkt rate 58.3%

120-day: Win 65.2%, Sample 23, Median +17.2%, Excess +5.52%, Beat mkt rate 56.5%

120 days after: historical avg +14.83%

20-day +0.22%
60-day +6.85%
120-day +14.83%
20-day
60-day
120-day
Win
50%
50%
65.2%
Sample
24
24
23
Median
-0.21%
+3.87%
+17.2%
Excess
-1.38%
+4.11%
+5.52%
Beat mkt rate
41.7%
58.3%
56.5%

Over 23 occurrences, 120-day forward avg gained 14.83%, beat the market by 5.52 pts; win rate 65.2%.

Filed revenue acceleration

Active · now 16.02%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2018-05-09)

Average forward return after Filed revenue acceleration

20-day: Win 46.2%, Sample 13, Median -4.19%, Excess +1.87%, Beat mkt rate 53.8%

60-day: Win 84.6%, Sample 13, Median +15.65%, Excess +12.34%, Beat mkt rate 84.6%

120-day: Win 75%, Sample 12, Median +36.98%, Excess +23.06%, Beat mkt rate 66.7%

120 days after: historical avg +30.18%

20-day +2.05%
60-day +15.79%
120-day +30.18%
20-day
60-day
120-day
Win
46.2%
84.6%
75%
Sample
13
13
12
Median
-4.19%
+15.65%
+36.98%
Excess
+1.87%
+12.34%
+23.06%
Beat mkt rate
53.8%
84.6%
66.7%

Over 12 occurrences, 120-day forward avg gained 30.18%, beat the market by 23.06 pts; win rate 75%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 10Insufficient data
20-40 79+88.6% +83.8% 100% +47.5%
40-60 386+48.4% +20.7% 93.5% +35.2%
60-80 546+25.4% +8.7% 61.4% +16%
80-100 You are here419+26.6% +30.5% 72.1% +6.8%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 193.14, placing it in the 95.6 own-history percentile, inside the 80-100 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Insufficient data
(13d)
+40.8%
Win rate 90.2% Excess +32.1%
234d
+10.6%
Win rate 50.4% Excess +3.4%
661d
60-day momentum down
+61.5%
Win rate 98.4% Excess +39%
63d
+24.8%
Win rate 78.9% Excess +21.8%
304d
Now
+36.3%
Win rate 54.4% Excess +25.6%
285d

Currently in “Expensive (own-history top third) × 60-day momentum down”: across 285 historical days, 120-day forward avg gained 36.3%, win rate 54.4%, beat the market by 25.6%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

19 times historically; 60-day forward avg +6.22%, win rate 57.9%, beating the market by +5.13 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

26 times historically; 60-day forward avg +11.96%, win rate 66.7%, beating the market by +7.68 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.